Articles tagged with Parkinsons Disease
Researchers have engineered probiotic bacteria to produce the dopamine precursor L-DOPA, a potential treatment for Parkinson's disease. The new approach eliminates side effects and reduces treatment complications, offering a promising alternative to existing treatments.
A new wireless implant has the potential to treat neuropathic pain resistant to medical therapy, offering a minimally invasive alternative to surgery. The device uses bioelectronic therapy to stimulate peripheral nerves from within blood vessels, providing precise placement and predictable outcomes.
Researchers at Boston University have developed optoacoustic neurostimulation with single neuron and subcellular level precision. Optoacoustic neuromodulation may offer advantages over ultrasonic neuromodulation, including higher spatial temporal resolution.
The Experimental Biology (EB) 2022 meeting features live presentations and a moderated Q&A session on groundbreaking studies. The virtual press conference reveals potential treatments for Parkinson's disease, COVID-19 vaccine-associated side effects, and alleviating food allergies.
Researchers developed an AI-driven image analysis pipeline that identified novel cellular hallmarks of Parkinson's disease from images of over a million skin cells. The platform can distinguish between patient cells and healthy controls, revealing new signatures for potential therapeutic targets.
A team at Harvard Medical School identified a mechanism that triggers local dopamine release in the brain when acetylcholine binds to axons, not previously known to initiate firing. This finding reveals more about the interaction between acetylcholine and dopamine systems, suggesting a new strategy for treating diseases like Parkinson's.
A study published in Nature Communications reveals a protein called CLUH that regulates mitochondrial fission, which is impaired in Parkinson's disease. Increasing CLUH levels can reverse symptoms in genetically engineered fruit flies with Parkinson's-like conditions.
A new study published in Neurology found that people taking statin drugs have a lower chance of developing parkinsonism later compared to those who were not taking statins. Statins may help reduce the risk due to their protective effect on arteries in the brain.
A novel system to control protein aggregation in a model of Parkinson’s disease suggests that aggregation of alpha-synuclein plays a critical role in disrupting neuronal homeostasis and triggering neurodegeneration. Light treatment led to formation of Lewy body-like aggregates, neurodegeneration, and Parkinson-like motor deficits in mice.
Scientists have identified a clear genetic signature of Parkinson's disease in people's memory T cells, which could lead to new therapies and diagnostics. The study found that targeting these genes may help stop T cells from attacking brain cells in Parkinson's.
Researchers at the University of Huddersfield have identified a key mechanism by which the coronavirus causes inflammation in the brain's immune cells, potentially explaining some symptoms experienced by COVID-19 patients. The study suggests that adequate funding is needed to further develop this research and its potential applications.
A gene called Fer2 has been identified as a key player in protecting dopaminergic neurons from degeneration. In flies and mice, overproduction of Fer2 reduces oxidative stress and prevents neurological defects characteristic of Parkinson's disease.
Researchers identify a neural circuit in midbrain, thalamus, and cortex that orchestrates neuronal activity to trigger planned movement. The discovery has important clinical implications for motor disorders like Parkinson's disease.
The study identifies nine key pathways that seem to be crucial in developing Parkinson's disease, some of which have not been linked before. The findings improve scientists' understanding of genetic risk factors for developing the disease and pave the way for personalized medicine.
A recent study found that individuals with a history of neurological or psychiatric conditions are at increased risk of developing a second condition. Women and men differ in their risk, with women being more likely to develop dementia after experiencing an earlier stroke.
A study published in Cell Metabolism shows that nicotinamide riboside supplementation significantly increases NAD levels in the human brain and improves Parkinson's disease symptoms, suggesting a potential new treatment approach.
Phosphorylated α-synuclein first appears at synapses near the site of inoculation, then spreads to axons and forms aggregates in neuronal cell bodies. This process begins in the synaptic region and may provide insight into prion-like propagation.
Multiple system atrophy (MSA) is a fatal neurodegenerative movement disorder with no effective treatments, progressing rapidly and impairing critical physiological functions. The researchers will investigate how misfolded protein aggregates contribute to disease pathogenesis using the NIH grant.
Researchers have created a portable device that can detect Parkinson's disease by analyzing the unique odor compounds on a person's skin. The 'e-nose' system showed an accuracy of 79.2% in diagnosing PD, with potential for improving diagnosis through machine learning algorithms.
A natural product from the dried root of Sophora flavescens, combined with an enzyme inhibitor, has been found to reduce neuroinflammation in a mouse model of Parkinson's disease. The compound kurarinone may provide hope for alleviating symptoms of the incurable disorder.
A new study from the University of Copenhagen has made significant breakthroughs in treating Parkinson's disease by targeting specific neurons in the brainstem. By stimulating excitatory neurons in the caudal area of the pedunculopontine nucleus, researchers were able to restore normal walking function in mice with Parkinson's symptoms.
Researchers at the University of Illinois Chicago found a promising treatment for neurodegenerative diseases by stopping nerve cell degeneration. A peptide has been identified that inhibits mitochondrial fission and lets nerve cells grow normally.
Researchers found that heart attack survivors were less likely to develop Parkinson's disease over a 21-year follow-up period. The study adjusted for various factors and found an inverse relationship between heart attacks and Parkinson's risk, suggesting cardiac rehabilitation should focus on preventing other cardiovascular diseases.
Researchers at Oregon State University have discovered a new class of potential drug targets for neurodegenerative conditions like Alzheimer's and Parkinson's. Oxidized proteins, such as Hsp90, can trigger cell death, and targeting these molecules may slow illness progression without side effects.
Researchers identified three KCTD proteins that modulate neurotransmitter activity, enabling fine-tuned movement. Their elimination enhances cAMP production and sensitivity to dopamine in neurons.
Salk researchers have engineered mammalian cells to be activated using ultrasound, a method that paves the way toward non-invasive versions of deep brain stimulation, pacemakers, and insulin pumps. The team found a protein called TRPA1, known for its role in responding to noxious compounds, which also opens in response to ultrasound.
Neurobiologists demonstrated that humans can unconsciously distinguish between even very similar sounds, but often don't recognize these differences. The study used EEG to measure brain responses to stimuli and found that the brain reacts differently to local and global irregularities in sound sequences.
A recent study found that people with Parkinson's Disease who consume more flavonoids have a lower mortality risk than those who don't. The researchers discovered that higher flavonoid intake is associated with improved survival rates in both men and women, particularly when it comes to anthocyanin-rich foods like berries and red wine.
A recent study found that individuals with Parkinson's disease who consume three or more servings per week of flavonoid-rich foods like berries, red wine, and tea have a lower chance of dying during the study period. Higher flavonoid consumption is associated with better survival rates in both men and women.
A new study found that disease-modifying antirheumatic drugs do not protect people with rheumatoid arthritis from developing Parkinson's disease. However, using chloroquine or hydroxychloroquine was associated with a lower risk of PD. The study controlled for various factors, including comorbidities and age.
Researchers found that CBN preserves mitochondrial function and prevents oxidative damage to nerve cells, suggesting potential for treating age-related neurodegenerative diseases like Alzheimer's. The compound works independently of cannabinoid receptors, making it a promising therapeutic option.
Researchers identified gaps in care and treatment for women with Parkinson's Disease, highlighting the need for personalized medicine and psychosocial support. The study calls for increased attention to sex and gender differences in PD management.
During the first wave of the COVID-19 pandemic in Canada, researchers found increased health service use and higher death rates among adults with dementia and Parkinson disease. The study examined changes in these populations compared to older adults without neurodegenerative diseases.
Regular aerobic exercise has been shown to strengthen brain networks between spared regions, improve grey-matter volume, and enhance movement control in individuals with Parkinson's disease. The study published in Annals of Neurology suggests that exercise can stimulate compensatory capacity in the brain, leading to reduced symptoms.
UC researchers received a $1.2 million grant to examine the impact of stress hormone receptors on cell degeneration in Parkinson's disease. The study aims to develop a new model that better replicates the progression of the disease, which may lead to treatments targeting stress hormone blockers or next-generation therapeutics.
A new study suggests that regular exercise can slow the progression of Parkinson's disease in people with early-stage symptoms. Those who engaged in moderate exercise for at least four hours a week experienced less trouble balancing, walking, and performing daily activities over time.
Researchers at the University of Bergen have discovered a new understanding of dopamine's regulatory mechanisms, which could lead to breakthroughs in treating neurodegenerative diseases. The study found that dopamine can bind to an enzyme called tyrosine hydroxylase, inactivating it and controlling its own production.
Researchers at Waseda University discovered a new protein isoform called Senp5S, which helps regulate Drp1 and mitochondrial dynamics during brain development. The study suggests a novel and vital role for post-translational SUMOylation in neuronal differentiation.
A new study led by Mount Sinai researchers found that microglia may play a critical role in some cases of brain disease, and provides a comprehensive guide for future studies. The study identified two new genes linked to brain disorders, including Alzheimer's and Parkinson's diseases.
Researchers have solved a decade-long mystery about the PINK1 protein, which plays a critical role in early onset Parkinson's disease. The discovery provides an unprecedented view of the protein and its activation process, paving the way for developing therapeutic agents that could slow or stop the progression of Parkinson's disease.
Researchers at Bar-Ilan University used a crowd-sourced approach to test the effectiveness of mannitol in treating Parkinson's disease. The study, published in BioSocieties, chronicles the story of CliniCrowd, an Israeli company that recruited patients and collected data on mannitol's effects.
Researchers found that a Parkinson's disease mutation mislocalizes iron in activated microglia, leading to toxic iron accumulation. This mislocalization may explain the disease's progression and provide a basis for therapies targeting LRRK2.
Researchers found that the SARS-CoV-2 N-protein accelerates the formation of amyloid fibrils in test tube experiments, interacting with α-synuclein protein. This interaction may contribute to the development of Parkinson's disease in COVID-19 patients.
Researchers at the University of Bath have optimised a peptide that prevents alpha-synuclein misfolding, a key feature of Parkinson's disease. The new molecule, 4654W(N6A), has shown significant promise in lab experiments and could lead to the development of a disease-modifying treatment.
Researchers have determined the molecular structure of TDP-43 aggregates extracted from human brains, shedding light on its role in neurodegenerative diseases like ALS. The discovery may lead to the development of targeted therapies and diagnostic tests.
A new study has identified a promising drug candidate to minimize uncontrolled muscle movements associated with Parkinson’s disease. PD13R reduced dyskinesia by more than 85% in animal studies, also improving sleep quality compared to other treatments.
Young veterans with mTBI experience premature cognitive decline in specific domains, matching elder normative scores and early-stage Parkinson's patients. The study highlights the significant negative impact of mTBI on cognitive function compared to healthy non-veterans.
The American Academy of Neurology has issued a guideline recommending treatment options for early Parkinson's disease, including levodopa as the best first treatment. The guideline also highlights potential side effects and risks associated with medications, such as dyskinesia and impulse-control disorders.
Researchers identified a significant vascular defect in patients with moderately severe Parkinson's disease, which may explain earlier study findings and provide a new target for therapeutic intervention. The discovery highlights the blood-brain barrier's crucial role in neurodegenerative diseases like Parkinson's.
Researchers at Newcastle University have found that increased levels of ceramides and alpha-synuclein protein in extracellular vesicles could help diagnose Lewy body dementia and test treatment effectiveness. The findings may lead to a more accurate diagnosis for the over 100,000 people affected by the disease.
Researchers have made significant breakthroughs in understanding Parkinson's disease, revealing that affected neurons don't die but lose properties. This knowledge opens the door to new therapeutic treatments targeting the cell body, rather than just axons.
Researchers have demonstrated the effectiveness of polymer-coated nanoparticles in delivering drugs to the brain, overcoming the blood-brain barrier challenge. The study showed that zwitterionic polymers improve accessibility but are rapidly absorbed by blood vessel walls.
Researchers will investigate brain circuits involved in the placebo effect and paradoxical kinesia, a phenomenon where Parkinson's patients exhibit normal motor function under specific circumstances. The study aims to identify new locations for deep brain stimulation placement and discover new treatments for Parkinson's disease.
Researchers developed a new NMR spectroscopic method to map IDP function more easily, fast, and accurately. The method sheds light on mechanisms of diseases like Parkinson's, Alzheimer's, and type 2 diabetes.
A new study found a significant increase in US Parkinson's disease deaths over the past two decades, with mortality rates twice as high in men as in women. White people were also more likely to die from the disease, potentially due to socioeconomic factors affecting access to healthcare.
Researchers have made significant progress in generating neurons in the lab, a potential therapeutic option for replacing lost neurons in neurodegenerative conditions like Parkinson's disease. A $9 million grant will support further research and development of this novel treatment approach.
A rhythmic approach to music therapy is being tested to improve fine motor skills in Parkinson's patients. The therapy uses specific combinations of rhythm and movement to reprogram brain frequencies, with promising results so far.
A preclinical study found that blocking the Bach1 protein slowed brain cell deterioration in Parkinson's disease. The researchers identified a potent inhibitor of Bach1 called HPPE, which protected cells from inflammation and oxidative stress, and showed promise as a potential therapeutic target.
Researchers at Duke University used new tools to monitor neurons and analyze machine learning data to see how zebra finches practice their courtship calls. They found that a neurotransmitter called noradrenaline shuts down variability in the song, making it more precise when performed under pressure.
Scientists at the University of Groningen developed wearable, stitchable, and sensitive sensors from flexible polymers and carbon fibre. These sensors can measure body position, movement, and touch, offering new possibilities for health monitoring and athlete performance tracking.